Alison D. Marshall

Nov 12, 2024 | mdpi.com | Alison D. Marshall |Anna Conway |Evan B. Cunningham |Heather Valerio

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Feb 14, 2024 | thelancet.com | Graham Cooke |Barnaby Flower |Evan B. Cunningham |Alison D. Marshall

Globally, more than 300 million individuals are living with hepatitis B or C. Deaths and disability caused by the long-term complications of these chronic infections—cirrhosis, liver failure, and hepatocellular carcinoma—represent a major public health challenge, comparable in scale to other major communicable diseases such as tuberculosis and malaria. In 2016, WHO set ambitious goals to eliminate viral hepatitis as a public health threat by 2030.

Jun 9, 2023 | implementationscience.biomedcentral.com | Anna Conway |Alison D. Marshall |Sione Crawford |Jeremy Hayllar |Jason Grebely |Carla Treloar

This analysis explores variation in how OAT providers relate their work in deimplementation to concepts of social inequity in health during the COVID-19 pandemic. Interviews were conducted with 29 OAT providers in New South Wales, Victoria, Queensland, Western Australia and Australian Capital Territory (59% doctors, 31% nurses, 10% service managers; average number of years working in OAT was 11).

May 30, 2023 | onlinelibrary.wiley.com | Heather Valerio |Maryam Alavi |Alison D. Marshall |Behzad Hajarizadeh

CONFLICT OF INTEREST STATEMENT Gregory J. Dore reports research support from Gilead and Abbvie. Jason Grebely  is a consultant or adviser for and has received research grants from AbbVie, Biolytical, Camurus, Cepheid, Gilead Sciences, Hologic, Indivor and Merck, and has received honoraria from AbbVie, Cepheid, Gilead Sciences and Merck outside the submitted work.